[{"id":"bf08ec17-5171-4452-9f04-c52123ce8ca4","acronym":"QUILT-3.017","url":"https://clinicaltrials.gov/study/NCT03476681","created_at":"2021-10-22T17:53:23.788Z","updated_at":"2024-07-02T16:35:03.580Z","phase":"Phase 1/2","brief_title":"Study of NEO-201 in Solid Tumors Expansion Cohorts","source_id_and_acronym":"NCT03476681 - QUILT-3.017","lead_sponsor":"Precision Biologics, Inc","biomarkers":" EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600","tags":["EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NEO-201"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 10/15/2025","primary_completion_date":" 10/15/2025","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-05-15"},{"id":"a033d9f2-b1be-4d3f-926c-ced213a7a05a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290433","created_at":"2021-01-18T00:59:21.701Z","updated_at":"2024-07-02T16:36:40.765Z","phase":"Phase 2","brief_title":"Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT00290433","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8 • ALK1","pipe":"","alterations":" ","tags":["TNFRSF8 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • dexamethasone • mesna • Depocyte (liposomal cytarabine) • Neupogen (filgrastim) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 07/01/2015","study_completion_date":" 07/01/2015","last_update_posted":"2020-09-23"},{"id":"06fa6d0c-d77a-44bd-bfad-6e5ced982114","acronym":"","url":"https://clinicaltrials.gov/study/NCT03181308","created_at":"2021-01-18T15:41:17.626Z","updated_at":"2024-07-02T16:36:43.875Z","phase":"Phase 1b","brief_title":"Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC","source_id_and_acronym":"NCT03181308","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" EGFR • PD-L1 • ROS1 • ALK1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 11/09/2017","start_date":" 11/09/2017","primary_txt":" Primary completion: 07/22/2019","primary_completion_date":" 07/22/2019","study_txt":" Completion: 07/22/2019","study_completion_date":" 07/22/2019","last_update_posted":"2020-06-24"},{"id":"01bd9776-4109-4734-9d40-8f7b153b539f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780010","created_at":"2021-01-18T18:41:47.734Z","updated_at":"2024-07-02T16:36:54.192Z","phase":"Phase 1b","brief_title":"Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC","source_id_and_acronym":"NCT03780010","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ALK1","pipe":"","alterations":" ","tags":["ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-10-28"}]